| Description | Beclabuvir (BMS-791325) is a potent NS5A replication complex inhibitor that inhibits the activity of the NS5B protein expressed by HCV genotypes 1, 2, 4, and 5 and is used in the study of HCV infection. |
| In vitro | Beclabuvir与 pegIFN/RBV 以及与一系列 DAAs（如 HCV NS5A 抑制剂、NS3 蛋白酶抑制剂和/或核苷类 NS5B 抑制剂）的 2 药或 3 药联用可显示出相加或协同的抗病毒活性 [2]。 |
| In vivo | Beclabuvir与daclatasvir和 asunaprevir的联合用药对全球最常见的基因型--HCV 基因型 1 感染者的病毒根除率非常高（约 90%）[1]。 |
| Target activity | NS5B protein:< 28 nM |
| Synonyms | BMS-791325 |
| molecular weight | 659.84 |
| Molecular formula | C36H45N5O5S |
| CAS | 958002-33-0 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 20 mg/mL (30.31 mM), Sonication is recommended. |
| References | 1. Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21 2. Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22(8):658-64. |